Cargando…
Development, Implementation, and Use of a Neurology Therapeutics Committee
Innovative therapeutics are transforming care of children with previously untreatable neurological disorders. However, there are challenges in the use of new therapies: the medicine may not be effective in all patients, administration may not be tolerated, and matching therapy choice to patient is c...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378459/ https://www.ncbi.nlm.nih.gov/pubmed/30800699 http://dx.doi.org/10.1177/2329048X19830473 |
_version_ | 1783395934361616384 |
---|---|
author | Clark, Edward B. Butterfield, Russell J. Filloux, Francis M. Bonkowsky, Joshua L. |
author_facet | Clark, Edward B. Butterfield, Russell J. Filloux, Francis M. Bonkowsky, Joshua L. |
author_sort | Clark, Edward B. |
collection | PubMed |
description | Innovative therapeutics are transforming care of children with previously untreatable neurological disorders. However, there are challenges in the use of new therapies: the medicine may not be effective in all patients, administration may not be tolerated, and matching therapy choice to patient is complex. Finally, costs are high, which imposes financial burdens on insurance companies, families, and the health-care system. Our objective was to address challenges for clinical implementation of the new therapeutics. We sought to develop a process that would be personalized for patient and disease, encourage appropriate use of a therapeutic agent while mitigating pressure on a clinician to prescribe the therapy in all instances, and assist third-party payers in approving therapeutic use based on safety and efficacy. We report our creation of a Neurology Therapeutics Committee for pediatric patients. We review the committee’s mechanisms, describe its use and report outcomes, and suggest the Neurology Therapeutics Committee’s broader applicability. |
format | Online Article Text |
id | pubmed-6378459 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-63784592019-02-22 Development, Implementation, and Use of a Neurology Therapeutics Committee Clark, Edward B. Butterfield, Russell J. Filloux, Francis M. Bonkowsky, Joshua L. Child Neurol Open Brief Communication Innovative therapeutics are transforming care of children with previously untreatable neurological disorders. However, there are challenges in the use of new therapies: the medicine may not be effective in all patients, administration may not be tolerated, and matching therapy choice to patient is complex. Finally, costs are high, which imposes financial burdens on insurance companies, families, and the health-care system. Our objective was to address challenges for clinical implementation of the new therapeutics. We sought to develop a process that would be personalized for patient and disease, encourage appropriate use of a therapeutic agent while mitigating pressure on a clinician to prescribe the therapy in all instances, and assist third-party payers in approving therapeutic use based on safety and efficacy. We report our creation of a Neurology Therapeutics Committee for pediatric patients. We review the committee’s mechanisms, describe its use and report outcomes, and suggest the Neurology Therapeutics Committee’s broader applicability. SAGE Publications 2019-02-14 /pmc/articles/PMC6378459/ /pubmed/30800699 http://dx.doi.org/10.1177/2329048X19830473 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Brief Communication Clark, Edward B. Butterfield, Russell J. Filloux, Francis M. Bonkowsky, Joshua L. Development, Implementation, and Use of a Neurology Therapeutics Committee |
title | Development, Implementation, and Use of a Neurology Therapeutics Committee |
title_full | Development, Implementation, and Use of a Neurology Therapeutics Committee |
title_fullStr | Development, Implementation, and Use of a Neurology Therapeutics Committee |
title_full_unstemmed | Development, Implementation, and Use of a Neurology Therapeutics Committee |
title_short | Development, Implementation, and Use of a Neurology Therapeutics Committee |
title_sort | development, implementation, and use of a neurology therapeutics committee |
topic | Brief Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378459/ https://www.ncbi.nlm.nih.gov/pubmed/30800699 http://dx.doi.org/10.1177/2329048X19830473 |
work_keys_str_mv | AT clarkedwardb developmentimplementationanduseofaneurologytherapeuticscommittee AT butterfieldrussellj developmentimplementationanduseofaneurologytherapeuticscommittee AT fillouxfrancism developmentimplementationanduseofaneurologytherapeuticscommittee AT bonkowskyjoshual developmentimplementationanduseofaneurologytherapeuticscommittee |